XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.1
PRODUCT REVENUE AND RESERVES FOR VARIABLE CONSIDERATION (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Summary of Product Revenues The Company recognized the following revenue from Vafseo and Auryxia (in thousands): 
Three Months Ended March 31,
Product
20252024
Vafseo
$12,034 $— 
Auryxia(1)
43,757 31,009 
Total product revenues
$55,791 $31,009 
(1) Includes the authorized generic version of Auryxia sold and distributed by the Company's authorized generic distribution partner, Mylan Therapeutics, Inc., or AG Partner, during the three months ended March 31, 2025.
Product Revenue Allowance and Reserve Categories
Product revenue allowance and reserve categories were as follows: 
(in thousands)Chargebacks
and Discounts		Rebates, Fees
and other
Deductions		Product ReturnsTotal
Balance at December 31, 2024$1,436 $15,726 $6,442 $23,604 
Current provisions related to sales in current year380 20,147 387 20,914 
Adjustments related to prior year sales69 400 (164)305 
Credits/payments made(1,389)(8,822)(145)(10,356)
Balance at March 31, 2025$496 $27,451 $6,520 $34,467 
(in thousands)Chargebacks
and Discounts		Rebates, Fees
and other
Deductions		Product ReturnsTotal
Balance at December 31, 2023$1,607 $22,991 $6,916 $31,514 
Current provisions related to sales in current year1,910 10,229 961 13,100 
Adjustments related to prior year sales(93)(1,374)(105)(1,572)
Credits/payments made(2,216)(18,282)(1,974)(22,472)
Balance at March 31, 2024$1,208 $13,564 $5,798 $20,570 
Changes in Contract Assets and Liabilities
The following table presents changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Partner (in thousands):
Three Months Ended March 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable
$— $1,241 $— $1,241 
Contract liabilities:
Deferred revenue
$— $1,241 $— $1,241 
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Three Months Ended March 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:    
Accounts receivable(1)
$2,010 $1,545 $(1,989)$1,566 
Three Months Ended March 31, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$3,333 $2,327 $(2,968)$2,692 
Contract liabilities:
Deferred revenue(2)
$43,296 $695 $— $43,991 
(1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia and Vafseo which are included in the accompanying unaudited condensed consolidated balance sheets as of March 31, 2025 and 2024.
(2) See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.